Infectious Disease established the medical treatment system from October 2012. Currently, my main work is consultation for cases of nosocomial infections, as well as follow-up of patients with positive blood cultures and infection control work. Diagnosis and treatment of common and rare infections are performed, and in close cooperation with General Medicine, we cooperate with all departments in the hospital to support difficult cases of infections and optimal antimicrobial drug treatment. and manage infectious disease patients together.
In addition, as a central acute hospital in Kobe City, our hospital has a class 1 infectious disease bed, and plays a central role in Kobe City even in infectious diseases such as Ebola virus infection, which is a hot topic in health administration. In addition, as an advanced medical institution, we also treat infectious diseases for immunocompromised patients who are outpatients or hospitalized, infectious diseases imported from overseas, and HIV infectious diseases.
Our hospital has a well-equipped microbiology laboratory, and we can use the information obtained quickly to diagnose infectious diseases, and it is also useful for infection control such as hospital-related infections.
In our outpatient clinic, we also provide vaccinations before travel and other health consultations before and after travel.
From common infectious diseases to emerging infectious diseases
- A detailed medical history and physical examination are used to assess and, if necessary, test and treat.
- We also treat rare infections and undiagnosed cases. It would be helpful if you bring your previous test results and treatment details along with the referral letter.
Main diseases/treatments
There are no specific tests, but tests such as blood/urine tests, culture tests (general bacteria, acid-fast bacteria, fungi, etc.), cerebrospinal fluid/pleural and ascitic fluid tests, and imaging tests (simple X-ray, CT, MRI, echo) are recommended. , Diagnosis and treatment are performed appropriately according to the need.
It plays a central role in the hospital in medical treatment and infection control related to COVID-19. Until the 6th wave, we have dealt with a wide range of cases, from mild to severe, with human support from the internal medicine and surgical departments, centering on the three clinical departments of Infectious Disease, Respiratory Medicine and emergency medicine.
From May 2022, with the establishment of medical treatment and infection control measures against COVID-19 and the development of in-hospital guidelines, mild and moderate COVID-19 will be handled by the entire internal medicine Infectious Disease. , I am in charge of cases of severe respiratory failure (requiring ventilator management, High-Flow Nasal Cannula, etc.) and refractory infections in severely immunocompromised patients. For COVID-19 patients hospitalized in other departments, provide advice to attending physicians regarding COVID-19 treatment and isolation period, and respond to patient questions related to disease and infection control And so on.
In addition, we are striving to standardize COVID-19 medical care and infection control within the hospital by creating and updating drug treatment guidelines and infection control manuals for the hospital and creating educational materials.
COVID-19 drug treatment guidelines version. 5 (updated on March 13, 2024)bacteremia, sepsis, meningitis, brain abscess, encephalitis, epidural abscess, peritonsillar abscess, malignant otitis externa, endophthalmitis, pneumonia, pulmonary empyema, empyema, infective endocarditis, mediastinitis, Cholecystitis, cholangitis, liver abscess, infectious enteritis, appendicitis, pyelonephritis, prostatitis, pelvic inflammatory disease, pyogenic vertebral disease, pyogenic arthritis, osteomyelitis, muscle abscess, cellulitis, necrotic muscle Meningitis, lymphadenitis, pressure ulcer infection, postoperative wound infection, catheter-related bloodstream infection, thrombophlebitis, febrile neutropenia, tuberculosis, syphilis, tetanus, nocardiosis, Japanese spotted fever, influenza, Measles, rubella, chickenpox, shingles, cytomegalovirus infection, malaria, dengue fever, etc.
Please refer to Travel Outpatient page.
Travel Outpatient page9-valent human papillomavirus vaccine, pneumococcal vaccine, influenza vaccine, herpes zoster vaccine (both inactivated and live vaccines are available), measles vaccine, rubella vaccine, varicella vaccine, mumps vaccine, Japanese encephalitis vaccine, tetanus Vaccines, etc., are available.
9-valent human papillomavirus vaccineTests such as blood/urine tests, culture tests (general bacteria, acid-fast bacteria, fungi, etc.), cerebrospinal fluid/pleural and ascitic fluid tests, and imaging tests (simple X-ray, CT, MRI, echo) are conducted to determine the need for diagnosis and treatment. We are doing it appropriately.
Medical record
Number of hospitalized patients by disease in our department 2020-2022
| 2020 | COVID-19: 319, Anaphylaxis: 1 |
| 2021 | COVID-19: 327 people |
| 2022 | COVID-19: 89, HIV infection: 1 |
Number of infectious disease consultations (other than COVID-19 and infection control)
| 2019 | 653 cases |
| 2020 | 665 cases |
| 2021 | 501 cases |
Number of positive blood culture rounds
| 2019 | 914 cases |
| 2020 | 834 cases |
| 2021 | 1041 cases |
clinical research
Notice Regarding Implementation of Clinical Research
Information disclosure date: February 15, 2017
For patients visiting the Infectious Disease
Currently, the Infectious Disease is conducting the following clinical research.
In this research, we will use the data (information) obtained from the patient's daily clinical practice.
If you would like to know more about the research plan or content, if you have any objections to the use of your data in this research, or if you have any other questions, please contact us at the contact information below. .
| Research subject name | Explanatory text (PDF) |
|---|---|
| On the 30-day survival rate of patients whose blood cultures were obtained at an outpatient clinic and who returned home after starting antibiotics, and whose blood cultures were positive for Gram-negative bacilli. | |
| 病院附属の保育園から病院内へのCOVID-19感染の影響に関する記述疫学研究 | |
| On the relationship between the environment and the isolation of Aspergillus from patient sputum in a prefabricated ward dedicated to COVID-19 | |
| A study to examine the effects of a mutant strain (VOC-202012/01) in novel coronavirus infections on clinical outcomes | |
| Cross-sectional study to understand the situation of new coronavirus infection in Kobe | |
| A cross-sectional study to understand the status of new virus infections in Kobe and a study on the accuracy of antibody tests | |
| A cross-sectional study to understand the status of novel virus infections in Kobe |
Multicenter retrospective study on the clinical background and course of capnocytophaga species infection
| Purpose of research | Clarifying the clinical picture of Capnocytophaga species infection, risk factors and treatment strategies by collecting and analyzing data obtained in normal medical care for patients in whom Capnocytophaga species was detected from blood and cerebrospinal fluid culture The purpose is to obtain knowledge that can be used as a reference when considering |
|---|---|
| Eligible patients | Patients who visited our department between January 1, 2007 and December 31, 2015, and for whom Capnocytophaga species were detected in blood and cerebrospinal fluid cultures. |
| Research period | From the date of approval by the clinical research ethics committee of our hospital to the end of March 2019 |
| Medical data to be used |
|
| Handling of Personal Information and Ethics | Research data may be provided to other facilities that are conducting joint research, but we will anonymize it by deleting information that can directly identify patients (names, medical record numbers, etc.), so our staff will Others cannot identify our patients. The results of this research may be presented at academic conferences and academic journals, but even in that case, the patient's privacy is protected because the patient's privacy is anonymized as described above. In addition, this research follows the guidelines set by the government and is being conducted with the review and approval of the clinical research ethics committee of our hospital. |
| Research Secretariat (point of contact for this research in general) | 自治医科大学付属さいたま医療センター 血液科 代表者名：鵜飼知嵩 住所：埼玉県さいたま市大宮区天沼町1-847 電話：048-647-2111 |
| Inquiries (our contact point) | 神戸市立医療センター中央市民病院 総合内科・感染症 研究責任医師：土井朝子 住所：神戸市中央区港島南町2丁目1-1 電話：078-302-4321 |
news
Handling of Gardasil 9 (9-valent human papillomavirus vaccine) has been updated.
Please check this out for details.
